Form 4: Arrowhead Pharmaceuticals CEO Christopher Anzalone Reports Stock Transactions

Arrowhead Pharmaceuticals' CEO, Christopher Anzalone, reports the acquisition of 340,000 shares and the sale of 51,425 shares to cover tax obligations.

Summary

• On March 13, 2025, Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, acquired 340,000 shares of common stock related to performance awards.
• These performance awards were granted on December 22, 2023, and certified on March 12, 2025, following the achievement of specific performance goals.
• On the same day, Anzalone sold 51,425 shares of common stock at a weighted average price of $15.07 to satisfy tax withholding obligations.
• The sales prices ranged from $14.83 to $15.76.
• Following these transactions, Anzalone beneficially owns 4,062,377 shares of Arrowhead Pharmaceuticals common stock, including shares underlying Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares based on performance is a good sign, but the sale of shares, even for tax purposes, can create some uncertainty.

Positives

• The acquisition of 340,000 shares indicates confidence in the company's performance and future prospects, as the shares were awarded upon achievement of performance goals.

Negatives

• The sale of 51,425 shares, even for tax obligations, could be perceived negatively by some investors, although it's a common practice.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are closely watched by investors for insights into management's confidence in the company's future.

Comparison to Industry Standards

• Executive compensation packages often include performance-based stock awards, aligning management's interests with those of shareholders.
• Sales of shares to cover tax obligations are a standard practice among executives receiving stock-based compensation.
• Comparing Anzalone's transactions to those of executives at similar-sized biotech companies (e.g., Alnylam, Ionis) could provide a benchmark for assessing the magnitude and frequency of such transactions.

Stakeholder Impact

• Shareholders may view the acquisition of shares positively, reflecting management's confidence.
• The sale of shares, while for tax purposes, could create short-term price volatility.

Key Dates